title: [Therapeutic outcome of onabotulinum toxin type A in patients with upper limb spasticity].
abstract: Onabotulinum toxin type A treatment for post-stroke upper limb spasticity was investigated to contribute to establishing a standard dosage for Japanese patients. A total of 100 patients participated in the study. The outcome one month (33.6±6.5 days) after the treatment was assessed by the Modified Ashworth Scale (MAS) to estimate the mean effect with a 10-unit injection and the standard dosage expected to improve MAS 1 degree. Average improvement of 263 muscles treated with a higher concentration of 10 units diluted in 0.2 ml was 0.207±0.414 degrees, and that of 231 muscles treated with a lower concentration of 10 units in 0.4 ml was 0.149±0.244 degrees without significant difference among diluted concentrations. To improve MAS 1 degree, 64.6±31.1 units were required for the pectoralis major, 51.2±21.3 units for the teres major, 111.7±48.0 units for the biceps brachii, 51.6±26.8 units for the brachioradialis, 54.1±23.2 units for the brachialis, 34.4±10.7 units for the pronator teres, 64.6±27.9 units for the flexor carpi radialis, 62.4±26.8 units for the flexor carpi ulnalis, 58.5±31.1 units for the flexor digitorum profundus, 69.7±35.1 units for the flexor digitorum superficialis, 24.6±13.4 units for the flexor pollicis longus, and 15.6±11.3 units for the adductor pollicis. Although the results shown here had no significant differences among concentrations, increasing the volume would disturb injection into small muscles, so we considered that a lower volume with a higher concentration should assure larger benefits. It is difficult to make effective injections into all spastic muscles within the officially permitted health insurance dosage of 240 units. Hence, it is advisable to increase the applicable upper limit based on safely achieved cumulative experience.
authors.affiliation: Department of Neurology, Nagoya City Rehabilitation and Sports Centre.
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Horimoto
authors.forename: Aki
authors.initials: A
authors.lastname: Inagaki
authors.forename: Mika
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: Kumi
authors.initials: K
authors.lastname: Kanbe
authors.forename: Hajime
authors.initials: H
authors.lastname: Tanaka
authors.forename: Reika
authors.initials: R
authors.lastname: Ando
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hibino
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Tajima
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Fukagawa
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Kabasawa
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A